Showing results (631-640 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 2, 2010
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractorinessSung Yong Oh, Chi Young Jeong, Soon Chan Hong, et al.
Investigational New Drugs|July 11, 2009
Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion responseGurpreet Kaur, Mohammad Athar, M Sarwar Alam
Investigational New Drugs|February 14, 2009
F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignanciesJing Li, Yang Meng, Yue Liu, et al.
Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.
Investigational New Drugs|May 26, 2010
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogsPamela W Lucas, Joanna M Schmit, Quinn P Peterson, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Investigational New Drugs|April 24, 2010
A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude miceJin-Bin Jia, Wen-Quan Wang, Hui-Chuan Sun, et al.
Investigational New Drugs|May 4, 2010
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymerAchillia Lakka, Ilias Mylonis, Sophia Bonanou, et al.
Investigational New Drugs|April 28, 2010
Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell lineYukako Fukushi, Masaharu Hazawa, Kenji Takahashi, et al.
Investigational New Drugs|November 1, 1990
4'-EPI-doxorubicin in advanced lung cancer. A phase II trialG Giaccone, M Donadio, G Bonardi, et al.
Pageof 372